Health & FitnessMedicineScienceLife Sciences

Behind the Breakthroughs

Inside Precision Medicine

Medicine is full of breakthroughs. Most don't become medicine. Behind the Breakthroughs explores scientific ideas that could change how we diagnose and treat disease—and what it will take for them to work. Host Jonathan D. Grinstein, PhD, a scientist-turned-journalist, speaks with the researchers, physicians, and entrepreneurs building the next generation of genetic medicines, diagnostics, AI, precision therapeutics, and biotechnology.

Hosted on Acast. See acast.com/privacy for more information.

Play

Open in

20 episodes
fortnightly
Avg 56 min
English

Episodes 20

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

#52
Wednesday · 46 min
Matt Begemann: The Cancer-Killing CRISPR
Senior Director of Research and Development at Confluence Genetics
#51
September 23 · 1 hr 2 min
Wei-Wu He: Craig Venter’s Legacy and the Future of Human Longevity
Executive Chairman of Human Longevity Inc. (HLI)
#50
September 9 · 59 min
Palani Kumaresan: Roche Diagnostics Is Ramping Up—Should Illumina Be Worried?
Global head of Roche Diagnostic Solutions
#49
August 26 · 51 min
Ken Greenberg: Can Ultrasound Shatter the Gene Therapy Delivery Bottleneck?
Founder and CEO of SonoThera
#48
August 12 · 42 min
David Thaisrivongs: Goldilocks and the First Oral PCSK9 Inhibitor
Executive Director and Head of Biocatalysis at Merck
#47
July 29 · 57 min
Beaubrun and Acharya: No Antibiotic Without a Diagnostic
The Cepheid-Fleming Initiative partnership tackling AMR
#46
July 15 · 1 hr
Amit Etkin: Precision Psychiatry’s Future Isn’t Genomics—It’s Brain Activity
Co-founder and CEO of Alto Neuroscience
#45
July 1 · 1 hr 2 min
Michael Antonov: From Virtual World Builder to Real-World Drug Designer
Co-founder and CEO of Deep Origin
#44
June 17 · 58 min
Philippe Pouletty: Turning Europe’s Life Science Startups Into World Leaders
CEO and Co-Founder Truffle Capital, Founder of Abivax and Carvolix
#43
June 3 · 1 hr
Arthur Caplan: The Right to Life, Liberty, and Pursuit of Health
Professor of Bioethics at New York University Grossman School of Medicine
#42
May 20 · 54 min
Carolina Aguilar: Brain-Computer Interfaces that Heal Neural Circuits
Co-founder and CEO at INBRAIN
#41
May 6 · 1 hr 7 min
Matthew Rabinowitz: Engineering a New Era of Diagnosis
Co-founder and Executive Chairman of Natera and Myome
#40
April 22 · 1 hr
Jurgi Camblong: Data-Driven Doctors Without Borders
Founder and CEO of SOPHiA Genetics
#39
April 8 · 51 min
Molly Gibson: Superintelligence and the Future of Drug Development
Origination Partner at Flagship Pioneering and Co-founder of Generate:Biomedicines, Lila Biosciences, and Expedition Medicines
#38
March 25 · 52 min
Mike Curtis: Pig Organs as a Bridge to Human Transplants
President and CEO of eGenesis
#37
March 11 · 48 min
Markus Warmuth: Eliminating Pathogenic Proteins with Molecular Glue Degraders
Traditional drugs usually inhibit specific protein sites, but many disease-causing proteins lack accessible or unique motifs, leaving them “undruggable.” Targeted Small-molecule drugs have long been the quiet workhorses of modern medicine, slipping inside cells to target disease-driving proteins, even as biologics, immunotherapies, and genetic medicines have taken center stage in recent years. Yet thousands of disease-related proteins remain “undruggable” because they lack the structural pockets needed for traditional inhibitors to bind. In this episode, Markus Warmuth, MD, CEO of Monte Rosa Therapeutics, explains how molecular glue degraders harness the cell’s protein-disposal machinery to eliminate harmful proteins entirely, and how the company’s QUEEN discovery platform is advancing new therapies in cancer and autoimmune disease. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.
#36
February 25 · 57 min
Alicia Zhou: The Dark Matter for Cancer Immunotherapy Translation
CEO at Cancer Research Institute (CRI)
#35
February 11 · 57 min
Brad Ringeisen: CRISPR for Disease Elimination and Humanitarian Solutions
Executive Director at Innovative Genomics Institute (IGI)
#34
January 28 · 56 min
Zachary Roberts: Building a Viable Off-the-Shelf CAR T
CMO and EVP of R&D at Allogene Therapeutics
#33
January 7 · 54 min
Boyang Wang: Organ Swaps and Mass Preventative Gene Therapy to Extend Lifespan
Founder of Immortal Dragons

Showing 1–20 of 20 episodes